20 November 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Posting of Annual Report and Accounts and Notice of Annual General Meeting
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that the Annual Report and Accounts for the year ended 30 June 2023 and Notice of its 2023 Annual General Meeting (AGM) were posted to shareholders today. These documents are available on the company's website at https://aptamergroup.com/.
Aptamer will host its AGM at 10:00 GMT on 15 December 2023 at Windmill House, Innovation Way, York, YO10 5BR. The AGM will be held in person only and there will be no new information presented at the meeting.
The results of voting on all resolutions at the AGM will be announced via a Regulatory News Service and the full results of the voting will be published on the Company's website, as soon as practicable after the conclusion of the AGM.
- ENDS -
For further information, please contact:
| Aptamer Group plc Steve Hull | +44 (0) 1904 217 404 |
| SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes | +44 (0) 20 3368 3550 |
| Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker | +44 (0) 20 3657 0050 |
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer® platform.
Optimer® binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer® binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer® technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.